Vertex Pharmaceuticals Financials - Benzinga

Vertex Pharmaceuticals Inc

VRTXNASDAQ

Trade with Public

Trade with Public

$551.57

23.384.43%

마지막 업데이트: Aug 19, 3:38 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Vertex Pharmaceuticals Financials

Vertex Pharmaceuticals (VRTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est

Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.

Benzinga Newsdesk

PRO
Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate

Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last

Benzinga Newsdesk

Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.

Avi Kapoor

Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone

CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.

Avi Kapoor

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

Vertex Pharmaceuticals Inc reported mixed financial results for Q1, with revenue of $2.99B and adjusted EPS of $4.47. CEO confident in future growth and value creation. Stock fell 2.7% and analysts revised price targets. Considering buying VRTX? Analysts have Outperform ratings and lowered price targets.

Avi Kapoor

Vertex Pharmaceuticals Posts Mixed Q1; Investors Focus On Non-CF Pipeline For Growth

Vertex Pharma posts revenue beat but misses EPS expectations. CF franchise remains strong, says Needham analyst.

Priya Nigam

© 2026 Benzinga | All Rights Reserved